DRL cries foul as US firm blocks Revlimid generics

Approaches FDA On Drug Risk Evaluation Rules Which Have Been Cited To Block It

Read More
Publication Date: 
31/08/2009
Economic Times (New Delhi)
Tags:
Cancer, Health, Drugs, Drug Industry, India